Pregnancy and Tirzepatide: the Clear Answer Before You Start or Stop

The biggest misconception: that 'not recommended' means the risk is mild or optional

Many people read 'not recommended in pregnancy' on a medicine leaflet and assume it is cautious legal boilerplate. With tirzepatide, the position is firmer than that. Animal reproductive toxicity studies (required as part of the licensing process) found adverse effects on foetal development at doses within the range relevant to human use. The data is detailed in the Mounjaro Summary of Product Characteristics, available via the electronic Medicines Compendium (eMC). Because of those findings, the manufacturers did not seek a pregnancy indication, and regulators did not grant one. There are no controlled human trials in pregnant women, and running such a trial would not be ethical given what animal data already shows. The MHRA's public guidance on GLP-1 medicines for weight loss reinforces that these medicines are unsuitable during pregnancy. 'Not recommended' here is the regulator's way of saying: the evidence base points firmly against it, and the absence of human data does not create a grey area, it closes one.

This matters practically. A woman who discovers she is pregnant several weeks into treatment has not necessarily caused harm, but she should stop immediately and speak to her GP or midwifery team the same day. Time on treatment is a conversation for clinicians who can review the full picture, not something to manage alone.

Trying to conceive: the wash-out period and the contraception question

The guidance for women who are planning a pregnancy is to stop tirzepatide before trying to conceive. The prescribing information advises that women of childbearing potential use effective contraception during treatment. NHS guidance on weight-management injections (published by NHS England) goes further on oral contraceptives specifically: because tirzepatide delays gastric emptying, the absorption of a daily pill taken by mouth may be reduced during the first weeks of treatment and after each dose increase. The practical instruction is to use an additional non-oral method, such as condoms, for the first four weeks of tirzepatide and for four weeks after stepping up to each new dose. There is no equivalent evidence of this effect with injectable semaglutide, but the principle of reviewing contraception before starting any GLP-1 medicine is sensible regardless. For detailed guidance on this specific interaction, our page on other substances and Mounjaro covers related absorption questions, and your prescriber or GP is the right person to advise on your individual contraceptive method. Questions about tirzepatide's effects on pregnancy, including what the animal data means in practice and how regulators have interpreted it, are covered in our dedicated resource on that topic, alongside our dedicated tirzepatide during pregnancy resource.

There is no established wash-out period stated in the UK SmPC for tirzepatide before attempting conception; the advice is to stop the medicine and discuss timing with your doctor, who can factor in your weight history and overall health picture. Women who have lost significant weight on tirzepatide may find that their fertility changes (weight loss itself can restore ovulatory cycles in women with conditions such as PCOS) so reliable contraception during treatment is important even if a previous pregnancy felt unlikely.

Breastfeeding: a similarly clear position

Tirzepatide is not recommended while breastfeeding. It is not known whether tirzepatide or its metabolites pass into human breast milk, and potential effects on a nursing infant have not been studied. In the absence of that data, the SmPC advises against use. This applies regardless of dose or how recently treatment began. Mothers who are breastfeeding and considering tirzepatide for weight management after birth should wait until breastfeeding has ended and then raise it with their GP or a clinician who can review the full situation. Our Mounjaro and pregnancy guidance covers the postnatal timing question in more depth, and this page on being pregnant on tirzepatide addresses the steps to take if treatment was ongoing when pregnancy was confirmed.

What this means if you are considering tirzepatide for weight management right now

For women who are not pregnant, not planning a pregnancy, and not breastfeeding, tirzepatide remains a licensed, effective option for weight management. The NHS England guidance on weight-management injections sets out the broader eligibility criteria and the contraception advice clearly. At nume, every prescription is written by a GPhC-registered Independent Prescriber who reviews your consultation in full, pregnancy status, contraceptive method and relevant history are all part of that assessment, not an afterthought. If your situation changes at any point during treatment, the right first call is to your prescriber or GP, not to wait until your next routine review. You can also reach our clinical team directly through our support page any day of the week. If you are ready to understand whether tirzepatide is suitable for you, check your eligibility with a free consultation. Our Mounjaro treatment page covers the full picture of how the medicine works, what to expect, and how the process runs, including the fact that your treatment arrives by tracked DPD delivery in plain, unbranded packaging, so discretion is never an issue. For context on the wider weight-management landscape, the weight loss treatments overview is a good starting point.